WhatsApp
backNews Article

Gland Pharma Achieves 23% Revenue Growth in Q2 FY2027 Driven by Expanding CDMO Segment and US Market

Strong US sales and new product launches support a 58% rise in profit after tax to INR 2,908 million in the quarter ending September 2026

Gland Pharma Limited posted Q2 FY2027 revenue of INR 18,336 million, a 23% increase year-on-year, driven by a 31% rise in CDMO revenues contributing 45% of total revenue. EBITDA grew 53% to INR 4,804 million, with adjusted EBITDA margins at 27%. The US market led growth with 42% revenue increase, supported by new product launches and expanding injectable and CDMO segments.

7 days ago|GLAND+0.33%
Gland Pharma LimitedGLANDEarnings Call Transcript

Gland Pharma Limited

Earnings Call Transcript

Gland Pharma Limited reported robust financial results for the second quarter of fiscal year 2027, with revenues increasing 23% year-on-year to INR 18,336 million and a 58% rise in profit after tax to INR 2,908 million. A significant contribution came from the Contract Development and Manufacturing Organization (CDMO) business, which grew by 31% and now represents nearly half of total revenues.

The company's EBITDA rose by 53% year-on-year to INR 4,804 million in Q2 FY2027, with adjusted EBITDA at INR 5,030 million and margins standing at 27%. Revenue growth was fueled by ongoing product launches, enhanced operating leverage, and expanding customer partnerships, especially in the CDMO segment.

Gland Pharma's CDMO revenues reached INR 8,227 million in the quarter, contributing approximately 45% of total revenue, driven by production under existing contracts and new manufacturing collaborations. The business pipeline remains strong, with recent additions in respiratory microspheres and specialty formulations.

The critical injectable business also delivered solid results with revenues of INR 10,109 million, growing 18% year-on-year, supported by strong demand and wider market penetration.

Geographically, the United States continues to be the largest market, with revenues increasing 42% year-on-year to INR 11,795 million, boosted by new product launches and increased volumes. Revenues from Europe and other regulated markets grew 23% to INR 4,110 million, while revenues from other global markets reached INR 2,044 million.

The company's French CDMO platform, Cenexi, recorded revenues of EUR 41 million but reported an EBITDA loss of EUR 6 million due to planned facility shutdowns, with expectations to return to profitability from the next quarter onwards.

Highlights

  • Q2 FY2027 revenue at INR 18,336 million, 23% YoY growth
  • EBITDA increased 53% YoY to INR 4,804 million with 27% adjusted margins
  • Profit after tax at INR 2,908 million, up 58% YoY
  • CDMO business revenue up 31% YoY to INR 8,227 million, 45% of total revenue
  • US market revenue grew 42% YoY to INR 11,795 million
  • Four new products launched in US during Q2 FY2027, expanding portfolio and market share

Key Data Snapshot

Q2 FY2027 Total RevenueINR 18,336 million
Q2 FY2027 EBITDAINR 4,804 million
Q2 FY2027 Adjusted EBITDAINR 5,030 million
Q2 FY2027 Adjusted EBITDA Margin27%
Q2 FY2027 Profit After TaxINR 2,908 million
Q2 FY2027 CDMO RevenueINR 8,227 million
Q2 FY2027 CDMO Revenue ShareApproximately 45%
H1 FY2027 Total RevenueINR 36,339 million
H1 FY2027 Profit After TaxINR 6,077 million
Q2 FY2027 US Market RevenueINR 11,795 million
Q2 FY2027 Revenues from Europe and Other Regulated MarketsINR 4,110 million
Quarterly Cenexi RevenueEUR 41 million
Quarterly Cenexi EBITDA LossEUR 6 million

What happened

  • Gland Pharma reported Q2 FY2027 revenue of INR 18,336 million, up 23% year-on-year.
  • EBITDA increased 53% year-on-year to INR 4,804 million with adjusted EBITDA margins at 27%.
  • Profit after tax rose 58% year-on-year to INR 2,908 million.
  • Contract Development and Manufacturing Organization (CDMO) business revenue grew 31% to INR 8,227 million, contributing 45% of total revenue.
  • US market revenues increased 42% to INR 11,795 million, driven by new product launches and volume growth.

Key details

  • CDMO revenues for first half FY2027 reached INR 17,142 million, representing 47% of consolidated revenues and 25% growth year-on-year.
  • Cenexi's quarterly revenues stood at EUR 41 million with an EBITDA loss of EUR 6 million due to planned annual shutdowns.
  • Critical injectable business revenue for Q2 FY2027 was INR 10,109 million, growing 18% year-on-year.
  • Company launched four new products in the US market during the quarter.
  • Growth also supported by commercial supply from signed CDMO contracts and expanded manufacturing partnerships.

Strategic context

  • The company is focusing on building its sterile injectables and CDMO platform as key long-term growth drivers.
  • Technology transfer activities and discussions with global clients continue to develop the CDMO pipeline.
  • Expanding capabilities in respiratory products and specialty formulations.
  • Plans to restore Cenexi profitability from Q3 onwards through optimizing capacity utilisation and cost control.

More News on Earnings Call Transcript

View all

Latest corporate announcements and market updates in Earnings Call Transcript.

View all news
Gland Pharma Achieves 23% Revenue Growth in Q2 FY2027 | Stockk News